10 Stocks Hedge Funds Are Selling in 2025
Hedge fund returns went up in July 2025, helped by stock markets reaching record highs, though some funds faced challenges from US trade uncertainties, according to a Goldman Sachs report.
Bristol Myers Squibb Co (BMY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Pzena Investment Management Richard S. Pzena | 14,843,475 | $687,104,458 | +11% | 2.23% |
| 2. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 11,311,281 | $523,599,197 | +429% | 0.37% |
| 3. | GLG Partners Noam Gottesman | 7,465,845 | $345,593,965 | +281% | 0.66% |
| 4. | AQR Capital Management Cliff Asness | 6,067,940 | $280,672,583 | +2% | 0.23% |
| 5. | 3,529,500 | $163,380,555 | -26% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.58 | 4,250 | $202,215.00 | 83,513 | 2025-04-25 | Filing | |
| $55.05 | 2,000 | $110,096.00 | 104,626 | 2025-02-20 | Filing | |
| $54.84 | 1,823 | $99,999.97 | 63,932 | 2025-02-14 | Filing | |
| $54.68 | 1,830 | $100,055.25 | 62,109 | 2024-11-01 | Filing | |
| $49.78 | 2,000 | $99,560.00 | 82,672 | 2023-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.23 | 378 | $16,718.94 | 5,066 | 2025-08-02 | Filing | |
| $38.01 | 97 | $3,701.83 | 0 | 2025-05-09 | Filing | |
| $55.62 | 700 | $38,930.50 | 11,760 | 2024-11-04 | Filing | |
| $61.25 | 17,986 | $1,101,642.50 | 27,868 | 2023-08-24 | Filing | |
| $61.14 | 732 | $44,754.48 | 6,584 | 2023-08-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 194,925,206 | $9,023,087,778 | 0.15% | |
| 2. | 172,226,329 | $7,972,356,792 | 0.15% | |
| 3. | 103,960,874 | $4,812,350,792 | 0.31% | |
| 4. | 94,739,994 | $4,385,514,322 | 0.16% | |
| 5. | 70,802,680 | $3,277,456,089 | 0.57% |
News See All
Jim Cramer Recently Shed Light on These 13 Stocks
“This market is driving the best investors I know crazy, and I know why: incredibly expensive stocks that shouldn't go up, go up endlessly, while stocks of perfectly good companies are completely ignored...
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (NYSE:BMY) is one of the top cheap pharmaceutical stocks to buy now.
11 Cheap Pharmaceutical Stocks to Buy Now
The White House announced on Thursday that President Trump sent 17 major pharmaceutical companies letters delineating the steps they should take to decrease the prices of US prescription drugs to “most...
Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu
Bristol-Myers Squibb Company (NYSE:BMY) ranks among the best medical stocks to buy according to analysts.
Bristol-Myers Squibb Company (NYSE:BMY) Q2 2025 Earnings Call Transcript
Operator: Good day, and welcome to the Bristol-Myers Squibb Second Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
11 Best Medical Stocks to Buy According to Analysts
As macroeconomic headwinds, regulatory reforms, and geopolitical concerns converge in the second half of 2025, PwC predicts that the health industry's resilience and adaptability will be put to the test...
Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025
Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best 52-Week Low Blue Chip Stocks to Buy Now.
10 Best 52-Week Low Blue Chip Stocks to Buy Now
With US markets touching all-time highs, foreign markets being relatively cheaper, and global investors being over-indexed to the US markets, ClearBridge Investments believes that it's easy to envision...
Why Investors View Bristol‑Myers Squibb (BMY) as a Safe Dividend Stock for Income
Bristol-Myers Squibb Company (NYSE:BMY) presents a strong case for investors looking for both value and reliable income.